Fernando Ovalle
Endocrinology, Diabetes & Metabolism · Birmingham, ALNPI 1104930916
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $13,198 of the $14,739 with a category attached, or 89.5%. 15 manufacturers reported payments, led by Bayer at 53.5% of the total. Reporting peaked in 2021 at $5,255 and has fallen 95.5% since, to $235 in 2025.
Across 32 payments — averaging $460.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$8K
- Merck$3K
- Novo Nordisk$2K
- Medtronic$337
- Intuitive Surgical$300
- Kowa Pharmaceuticals America, Inc.$116
- plus $487 from 9 others
Across 119 payments — averaging $4215.69 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$112K
- Dompe Farmaceutici S.p.a.$104K
- Xeris Pharmaceuticals, Inc.$91K
- AbbVie$82K
- Chiesi USA, Inc.$44K
- Sanofi US Services Inc.$29K
- plus $39K from 4 others
What the payments were for
- Consulting fees$13,19890%
- Speaking & faculty fees$3002%
- Food & beverage$1,2178%
- Education$240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 7 | $7,880 |
| Merck | 3 | $3,369 |
| Novo Nordisk | 4 | $2,250 |
| Medtronic | 4 | $337 |
| Intuitive Surgical | 1 | $300 |
| Kowa Pharmaceuticals America, Inc. | 1 | $116 |
| Abbott | 4 | $88 |
| Corcept Therapeutics | 1 | $83 |
| Sanofi-aventis U.S. LLC | 1 | $81 |
| Amgen | 1 | $70 |
| Amryt Pharma Holdings Ltd | 1 | $65 |
| BETA Bionics, Inc. | 1 | $34 |
| Boehringer Ingelheim | 1 | $27 |
| Neurocrine Biosciences, Inc. | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered$6,180
- Kerendia$1,700
- Da Vinci Surgical System$300
- MINIMED 780G$228
- Livalo$116
- STEGLATRO$114
How this compares
$14,739 in reported general payments places this provider in the 75th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 140 | $204,790 |
| MounjaroTirzepatide | 105 | $112,453 |
| JardianceEmpagliflozin | 88 | $79,000 |
| TrulicityDulaglutide | 48 | $47,268 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 26 | $33,518 |
| Tresiba Flextouch U-100Insulin Degludec | 53 | $33,131 |
| Humulin R U-500Insulin Regular, Human | 11 | $29,337 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 26 | $28,158 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 11 | $21,567 |
| FiaspInsulin Aspart (Niacinamide) | 15 | $18,645 |
| Humalog Kwikpen U-100Insulin Lispro | 54 | $15,499 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 114 | $13,696 |
| HumalogInsulin Lispro | 25 | $13,102 |
| NovologInsulin Aspart | 24 | $12,729 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 16 | $11,201 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $2,250 | $236,164179 claims |
| Boehringer IngelheimJardiance | $27 | $79,00088 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Birmingham
- Ralph TeagueBirmingham$487K
- William GarveyBirmingham$421K
- Edison GoncalvesBirmingham$142K
- Fernando BrilBirmingham$74K
- Rodrigo ValderramaBirmingham$61K
- Janelle TownesBirmingham$56K
- Richard RosenthalBirmingham$24K
- Jennifer SohnBirmingham$14K
- Jorge PinoBirmingham$14K
- Malek KarassiBirmingham$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.